Phase i study of atacicept in relapsed/refractory multiple myeloma (MM) and Waldenström's macroglobulinemia

Clinical Lymphoma, Myeloma and Leukemia

Volumn 11, Issue 1, 2011, Pages 136-138

  Rossi, Jean François ^a  

^a HÔPITAL SAINT ELOI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

APRIL PROTEIN; ATACICEPT; IMMUNOGLOBULIN; POLYCLONAL ANTIBODY; SYNDECAN 1;

ADULT; AGED; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONFERENCE PAPER; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFECT; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION; LUNG DISEASE; LYMPHOCYTE COUNT; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PHASE 1 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; WALDENSTROEM MACROGLOBULINEMIA;

EID: 79953684902     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.3816/CLML.2011.n.031     Document Type: Conference Paper

References (23)

1. Schneider P, MacKay F, Steiner V, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999; 189:1747-56 (Pubitemid 29272691)
2. Moreaux J, Legouffe E, Jourdan E, et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 2004 ; 103:3148-57. (Pubitemid 38451693)
3. Novak AJ, Darce JR, Arendt BK, et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 2004; 103:689-94. (Pubitemid 38140105)
4. Von Bulow GU, Bram RJ. NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily. Science 1997; 278:138-41. (Pubitemid 27446295)
5. Gras MP, Laabi Y, Linares-Cruz G, et al. BCMAp: an integral membrane protein in the Golgi apparatus of human mature B lymphocytes. Int Immunol 1995; 7:1093-106.
6. Thompson JS, Bixler SA, Qian F, et al. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 2001; 293:2108-11. (Pubitemid 32848062)
7. Moreaux J, Cremer FW, Reme T, et al. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood 2005; 106:1021-3.
8. Abe M, Kido S, Hiasa M, et al. BAFF and APRIL as osteoclast-derived survival factors for myeloma cells: a rationale for TACI-Fc treatment in patients with multiple myeloma. Leukemia 2006; 20:1313-5. (Pubitemid 43905843)
9. Tai YT, Li XF, Breitkreutz I, et al. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res 2006; 66:6675-82. (Pubitemid 44085624)
10. Yaccoby S, Pennisi A, Li XY, et al. Atacicept (TACI-Ig) inhibits growth of TACI(high) primary myeloma cells in SCID-hu mice and in coculture with osteoclasts. Leukemia 2008; 22:406-13. (Pubitemid 351250547)
11. Elsawa SF, Novak AJ, Grote DM, et al. B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom macroglobulinemia. Blood 2006; 107:2882-8.
12. Gross JA, Dillon SR, Mudri S, et al. Shoemaker K, Vu T, Moore M, Grossman A, Clegg CH. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease: impaired B cell maturation in mice lacking BLyS. Immunity 2001; 15:289-302. (Pubitemid 32816877)
13. J-F Rossi, J Moreaux, D Hose, et al. Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study. Br J Cancer 2009; 101:1051-58.
14. Munafo A, Priestley A, Nestorov I, et al. Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers. Eur J Clin Pharmacol 2007; 63:647-56. (Pubitemid 46911347)
15. Tak P, Thurlings R, Rossier C, et al. Atacicept in patients with rheumatoid arthritis: Results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis and Rheum 2008, 58:61-72.
16. Dall'Era M, Chakravarty E, Wallace D, et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 2007; 56:4142-50. (Pubitemid 350262342)
17. Klein B, Li XY, Lu ZY, et al. Activation molecules on human myeloma cells. Curr Top Microbiol Immunol 1999; 246:335-41. (Pubitemid 29225993)
18. Mahtouk K, Hose D, Raynaud P, et al. Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma. Blood 2007; 109:4914-23. (Pubitemid 46827789)
19. Hendriks J, Planelles L, de Jong-Odding J, et al. Heparan sulfate proteoglycan binding promotes APRIL-induced tumor cell proliferation. Cell Death Differ 2005; 12:637-48. (Pubitemid 40767166)
20. Ingold K, Zumsteg A, Tardivel A, et al. Identification of proteoglycans as the APRIL-specific binding partners. J Exp Med 2005; 201:1375-83. (Pubitemid 40664082)
21. Moreaux J, Sprynski AC, Dillon SR, et al. APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop. Eur J Haematol 2009; 83:119-29.
22. Treon SP, Branagan AR, Hunter Z, et al. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenström's macroglobulinemia. Ann Oncol 2004; 15:1481-3. (Pubitemid 39409737)
23. Ansell SM, Witzig TE, Inwards DJ, et al. Phase I clinical study of atacicept in patients with relapsed and refractory B-cell non-Hodgkin's lymphoma. Clin Cancer Res 2008; 14:1105-10. (Pubitemid 351302557)